(Reuters) – Novavax Inc’s vaccine reduces the risk of mild-to-severe COVID-19, U.S. Food and Drug Administration staff said in briefing documents published on Friday.
A panel of FDA’s outside experts is scheduled to discuss authorization of the vaccine in adults next week.
(Reporting by Manas Mishra in Bengaluru; Editing by Amy Caren Daniel and Saumyadeb Chakrabarty)
